Timber Pharmaceuticals logo
Timber Pharmaceuticals TMBR
report update icon

Quarterly report 2023-Q2
added 05-16-2026

Timber Pharmaceuticals Cash Flow 2022-2010 | TMBR

Brief cash flow overview of Timber Pharmaceuticals

Cash flows are assessed across five available annual periods spanning 2018 to 2022.

Operating cash flow ended negative at -$15.9 million. Core operations are not yet producing a sustainable inflow.

Positive operating cash flow appeared only 0 times out of five; a stable cash profile has not formed.

Cash flow takeaway

Timber Pharmaceuticals has limited cash flow resilience; a return to stable positive cash generation is the main condition for improvement.

Annual Cash Flow Timber Pharmaceuticals

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010

Operating Cash Flow

-15.9 M -9.31 M -8.29 M -1.02 M -15.6 M -15.7 M - - - -1.08 M -51 K -5.79 K -

Depreciation & Amortization

4.09 K 1.43 K 61 K 62 K 52 K 141 K 56 K 1 K 25 K 5 K 1 K 207 -

Accounts Payables

1.35 M 953 K 395 K 501 K 1.38 M 2.55 M 1.78 M 1.15 M 486 K 229 K - - -

Accounts Receivables

- - - 4 K 7 K 4 K 7 K 1 K 2 K - - - -

Total Inventories

- - - - 10 K 38 K 100 K 160 K 138 K - - - -

All numbers in USD currency

Quarterly Cash Flow Timber Pharmaceuticals

2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Operating Cash Flow

-6.56 M -3.9 M - -12.7 M -8.53 M -2.94 M - -6.97 M -4.2 M -1.85 M - -6.6 M -5.08 M -1.08 M - -8.79 M -6.55 M -3.33 M - -11.9 M -8.37 M -3.6 M - - -8.37 M -4.23 M - -10.8 M -7.19 M - - - - - - -3.5 M -2.32 M -956 K - -670 K -265 K -33 K -5.72 K -10.9 K -7.95 K -22.5 K -4.2 K -5.78 K -5.76 K -4.2 K

Depreciation & Amortization

2.67 K 1.29 K - 2.92 K 1.79 K 787 - 791 175 14 K - - - - - 46 K 30 K 14 K - 38 K 24 K 12 K - 51 K 33 K 16 K - 36 K 21 K 8 K - 36 K 21 K 8 K - 10 K 4 K 1 K - 6 K 4 K 1 K 52 154 102 465 51 155 51 51

Accounts Payables

1.63 M 1.01 M 1.35 M 953 K 420 K 819 K 953 K 1.04 M 1.39 M 524 K 395 K 566 K 613 K 395 K 501 K 687 K 937 K 1.18 M 1.38 M 2.01 M 2.37 M 2.31 M 2.55 M 2.84 M 3.42 M 2.39 M 1.78 M 1.76 M 3.33 M 1.78 M - 1.76 M 3.33 M 1.78 M 486 K - - - 229 K - - - - - - - - - - -

Accounts Receivables

- - - - - - - - - - - - - - 4 K 4 K 16 K 5 K 7 K 8 K 2 K 3 K 4 K 7 K 1 K 6 K 7 K 9 K 33 K 6 K - 9 K 33 K 6 K 2 K - - - - - - - - - - - - - - -

Total Inventories

- - - - - - - - - - - - - - - 10 K 13 K 6 K 10 K 15 K 20 K 30 K 38 K 77 K 112 K 76 K 100 K 336 K 364 K 215 K - 336 K 364 K 215 K 138 K - - - - - - - - - - - - - - -

All numbers in USD currency

Cash Flow Statement is one of the three key financial reports of the company Timber Pharmaceuticals, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
ADC Therapeutics SA ADC Therapeutics SA
ADCT
$ 1.31 6.5 % $ 166 M schweizSchweiz
ADMA Biologics ADMA Biologics
ADMA
$ 9.7 3.21 % $ 2.31 B usaUSA
Adaptive Biotechnologies Corporation Adaptive Biotechnologies Corporation
ADPT
$ 27.89 0.3 % $ 4.23 B usaUSA
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 13.3 1.06 % $ 364 M israelIsrael
AbbVie AbbVie
ABBV
$ 265.08 0.02 % $ 469 B usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 193.45 0.24 % $ 9.62 B usaUSA
Aytu BioScience Aytu BioScience
AYTU
$ 2.28 2.24 % $ 28.1 M usaUSA
Adagene Adagene
ADAG
$ 2.97 0.62 % $ 175 M chinaChina
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.53 2.65 % $ 293 M usaUSA
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 4.04 0.24 % $ 2.7 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 62.21 0.06 % $ 11.9 B usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.16 0.45 % $ 3.56 M israelIsrael
Achieve Life Sciences Achieve Life Sciences
ACHV
$ 7.83 0.87 % $ 341 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 14.19 1.17 % $ 1.27 B usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
C4 Therapeutics C4 Therapeutics
CCCC
$ 3.08 0.3 % $ 255 M usaUSA
Codexis Codexis
CDXS
$ 1.38 0.72 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cerus Corporation Cerus Corporation
CERS
$ 2.6 4.3 % $ 496 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.26 1.48 % $ 148 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.12 0.28 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.04 4.94 % $ 49.3 M israelIsrael
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.31 0.12 % $ 3.68 B canadaCanada
Aclaris Therapeutics Aclaris Therapeutics
ACRS
$ 5.26 2.69 % $ 645 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.19 1.26 % $ 13.4 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.45 1.05 % $ 711 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 112.94 3.29 % $ 11.7 B usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.74 0.19 % $ 103 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.31 0.74 % $ 87.6 M usaUSA
Curis Curis
CRIS
$ 0.95 0.98 % $ 12.5 M usaUSA
CorMedix CorMedix
CRMD
$ 7.69 0.06 % $ 554 K usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 55.76 1.2 % $ 5.01 B schweizSchweiz
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 12.54 8.21 % $ 990 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.71 2.62 % $ 3 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.68 0.59 % $ 13.5 M usaUSA
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 65.81 0.04 % $ 7.9 M usaUSA
Axon Enterprise Axon Enterprise
AXON
$ 450.61 1.61 % $ 35.2 B usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.56 7.16 % $ 355 M usaUSA
Denali Therapeutics Denali Therapeutics
DNLI
$ 20.46 5.52 % $ 3.53 B usaUSA
Precision BioSciences Precision BioSciences
DTIL
$ 6.36 10.62 % $ 81.6 M usaUSA
Dyadic International Dyadic International
DYAI
$ 0.41 3.72 % $ 14.8 M usaUSA
Editas Medicine Editas Medicine
EDIT
$ 2.69 0.17 % $ 239 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 3.97 1.46 % $ 22.5 M usaUSA